We found a significant enrichment of the KRT4/KRT13 signature in preinvasive lesions, from metaplasia to carcinoma in situ (CIS), as well as in invasive tumors, when compared to normal (metaplasia p=8x10-5; mild dysplasia p=0.0033; moderate dysplasia p=1.4x10-5, severe dysplasia p=3.7x10-5, CIS p=9.4x10-6, LUSC p=6x10-4) (Figure 4H). The gene discussed is KRT13; the disease is in situ carcinoma.